Europe Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type, Application, Source, and Type

The Europe organoids market is expected to grow from US$ 842.19 million in 2022 to US$ 4,080.52 million by 2030. It is estimated to grow at a CAGR of 21.8% from 2022 to 2030.

Growing Adoption of Personalized Drugs in Europe Organoids Market

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.

The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene-drug association treatment, identification of new therapies, and prediction of patient outcomes.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Europe Organoids Market Overview

The Europe organoids market is sub-segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. The regional market growth is associated with the rising demand for tissue engineering and organ transplantation; increasing adoption of organoids for disease modeling, gene mutation, and tumor modeling; and growing research activities on organoids. In addition, factors such as increased funding and public-private investments will likely add more opportunities in the coming years in the region.

Europe Organoids Market Revenue and Forecast to 2030 (US$ Million)

Europe Organoids Market Segmentation

The Europe organoids market is segmented into organ type, type, application, source, and country.

Based on organ type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the Europe organoids market in 2022.

Based on type, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the Europe organoids market in 2022.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the Europe organoids market in 2022.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the Europe organoids market in 2022.

Based on country, the Europe organoids market is segmented into the Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Germany dominated the Europe organoids market in 2022.

Cellesce, Definigen, Hubrecht Organoid Technology, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe organoids market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe organoids market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Europe organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.